News / Taiwan / economic_daily
Pei-Er Biomedical Hits Record High Ahead of 1-for-20 Stock Split
Health Technology · Biotechnology · economic_daily · 2026-08-26
6949
Pei-Er Biomedical shares surged to a record high of NT$1,490 as the company approaches its final trading day before a 1-for-20 stock split.
What Happened
Record Share Price: Pei-Er Biomedical reached a new all-time high of NT$1,490 today, cementing its position as a standout performer in the biotechnology sector. The rally is driven by both investor optimism regarding its pipeline and the upcoming corporate action involving a stock split.
Stock Split Details: The company is executing a 1-for-20 stock split, reducing the par value per share from NT$10 to NT$0.5. August 26 marks the final trading day for existing shares, with new shares expected to resume trading on September 7; the company's total market capitalization remains unchanged by this adjustment.
Clinical Pipeline: The company's lead product, PL001, is a CAR-T cell therapy targeting relapsed or refractory B-cell lymphoma. Having successfully passed the interim analysis of its Phase II clinical trial, the company is now focused on securing conditional drug approval to accelerate commercialization.
Investor Outlook: Investors are advised that the post-split share price will be adjusted proportionally to the split ratio, meaning the lower nominal price does not reflect a change in company value. Future performance will depend heavily on the progress of regulatory approvals and the successful commercial rollout of its CAR-T therapies.